Navigation Links
Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness

l impaction that may require manual removal.

About Methylnaltrexone

Methylnaltrexone is an investigational drug that is being studied as a treatment for the peripheral side effects of opioid analgesics. It is designed to mitigate the effect of opioids on peripheral receptors without interfering with central nervous system pain relief. Methylnaltrexone is being developed in subcutaneous and oral forms to treat opioid-induced constipation and an intravenous form for the management of post-operative ileus (POI).

(PGNX-C)

About the Companies

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of human immunodeficiency virus (HIV) infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus.

In the area of HIV infection, the Company is developing the viral-entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the HIV co-receptor CCR5. Recently, the Company announced positive results from its phase 1b trial of PRO 140 in HIV-infected individuals. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immunotherapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics also is developing vaccines designed to stimulate an immune response to PSMA and has a recombinant
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Calif. , Aug. 27, 2014 Asterias ... U.S. Food and Drug Administration (FDA) to initiate a ... patients with complete cervical spinal cord injury.  The approved ... clinical study of the product, and is designed to ... in patients with complete cervical spinal cord injuries, the ...
(Date:8/26/2014)... Aug. 26, 2014  Kewaunee Scientific Corporation (Nasdaq: ... quarter ended July 31, 2014. Sales for ... $32,003,000 in the first quarter last year. Net earnings ... share, as compared to net earnings of $1,587,000, or ... the prior year. However, both sales and earnings in ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... two fidaxomicin Phase 3 trials in patients with ... Meeting of the Infectious Disease Society of America (IDSA) ... investigator Derrick Crook, M.D., of the University of Oxford, ...
... leading home health care and hospice company (Nasdaq: AMED ... home care in this week,s issue of the New England Journal ... Advisory Board. Titled, "Why Health Care is Going ... home care as an increasingly crucial component of America,s health care ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
(Date:8/27/2014)... 2014 Top10BestSEOHosting.com compares many popular ... are the most recommended suppliers for webmasters who ... , “GreenGeeks and GoDaddy provide stellar hosting products ... they have managed to provide a wide range ... ease of use that helps diminish the inherent ...
(Date:8/27/2014)... and Ontario, Canada (PRWEB) August 27, 2014 ... through a huge transformation as was revealed in a ... 2014 survey were not just surprising but astonishing as ... survey carried out online interviewed existing members on the ... Facebook. , According to Kaly, 10yeargap marketing department manager," ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Discover Leadership ... personal and corporate transformation through their comprehensive leadership programs. ... Moses has unparalleled experience in the realm of outcome-focused ... this expertise in a new webinar series titled, “A ... Seller.” The first of this two part webinar is ...
(Date:8/27/2014)... NY (PRWEB) August 27, 2014 Overcoming a ... he finally found his niche. The Women’s Radio Network, WRNW1, ... for his continued support and dedication to the WRNW1 family. ... able to have such a positive atmosphere.” After KC Armstrong ... Sirius XM of the Howard Stern show, “Howard 100 News,” ...
(Date:8/27/2014)... 2014 Casey Diekman, assistant professor of ... is helping to gain greater insight into the biological ... Evolution has harmonized the behavior of humans and all ... the cycle of light and dark experienced each day ... hormone production related to natural patterns of sleep/wake behavior ...
Breaking Medicine News(10 mins):Health News:Excellent Hosting Suppliers Recommended By Top10BestSEOHosting.com 2Health News:Survey Reveals Younger Women Dating Older Men 2Health News:Survey Reveals Younger Women Dating Older Men 3Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4
... bars are completely interchangeable in the Medifast 5 & ... Medifast, Inc.,(NYSE: MED ), a leading portion-controlled weight-loss ... featuring a great crunchy,taste and a new formula that ... bar flavors include Chocolate Mint Crunch,Peanut Butter Crunch, and ...
... pathway may affect esophageal cancer risk, a dangerous and rapidly ... The University of Texas M. D. Anderson Cancer Center. , ... at the association between variations in genes related to microRNAs ... of Cancer Prevention Research , a journal of the ...
... Health Care recognizes health care ... Award, OAKLAND, Calif., Nov. 5 The California ... the "Director,s,Right Care Initiative Award" for its outstanding work ... presentation of the award and is,part of the DMHC,s ...
... the key factors that health professionals need to be aware ... Researchers from the University of Sheffield, UK, found considerable differences ... 16 viewed a series of sexual scenarios. , "The ... likely to see their partner,s point of view and were ...
... employers cost-effective, turnkey solution,to improve employee health., ... now have a,cost-effective solution to reduce employee ... competitive by attracting and retaining talent. Today,HealthFitness ... - a powerful combination of its eHealth ...
... CITY, China, Nov. 5 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, ... manufactures, and markets generic and branded,bio-pharmaceutical products in ... 2008 results on Friday, November 7, 2008. In ... at 10:00 a.m. EST on Friday,November 7, 2008 ...
Cached Medicine News:Health News:Medifast Adds New Crunchy Bars to Product Line 2Health News:Gene variations alter risk of esophageal cancer 2Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 2Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 3Health News:Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention 4Health News:Alcohol advice needs to play a greater role in sex education for teenagers 2Health News:Alcohol advice needs to play a greater role in sex education for teenagers 3Health News:HealthFitness Launches New Preventive Health Solution for Small Employers 2Health News:HealthFitness Launches New Preventive Health Solution for Small Employers 3Health News:China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008 2Health News:China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008 3
Inquire...
... damaged fiber optics reduce the light output to ... in the optical clarity that is so vital. ... essential to prevent further damage and more extensive ... can inspect your cables for you at no ...
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
Medicine Products: